Compare SHC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | IOVA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 1.6B |
| IPO Year | 2020 | 2008 |
| Metric | SHC | IOVA |
|---|---|---|
| Price | $15.72 | $3.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $20.33 | $9.00 |
| AVG Volume (30 Days) | 2.3M | ★ 12.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | 14.84 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,163,617,000.00 | N/A |
| Revenue This Year | $7.51 | $47.74 |
| Revenue Next Year | $6.00 | $40.31 |
| P/E Ratio | $175.28 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $10.94 | $1.67 |
| 52 Week High | $19.85 | $5.63 |
| Indicator | SHC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 50.75 | 50.04 |
| Support Level | $15.00 | $2.07 |
| Resistance Level | $16.47 | $4.35 |
| Average True Range (ATR) | 0.53 | 0.34 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 50.61 | 23.93 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.